Available online at www.sciencedirect.com

ScienceDirect

Current Opinion in Immunology

HIV and mucosal barrier interactions: consequences for transmission and pathogenesis

Adam Burgener[1,2,3], Ian McGowan[4,5] and Nichole R Klatt[6,7]

The mucosal barrier plays an integral function in human health as it is the primary defense against pathogens, and provides a critical transition between the external environment and the human internal body. In the context of HIV infection, the most relevant mucosal surfaces include those of the gastrointestinal (GI) and genital tract compartments. Several components help maintain the effectiveness of this mucosal surface, including the physical anatomy of the barrier, cellular immunity, soluble factors, and interactions between the epithelial barrier and the local microenvironment, including mucus and host microbiota. Any defects in barrier integrity or function can rapidly lead to an increase in acquisition risk, or with established infection may result in increased pathogenesis, morbidities, or mortality. Indeed, a key feature to all aspects of HIV infection from transmission to pathogenesis is disruption and/or dysfunction of mucosal barriers. Herein, we will detail the host–pathogen relationship of HIV and mucosal barriers in both of these scenarios.

Addresses
[1] National Laboratory for HIV Immunology, Public Health Agency of Canada, Winnipeg, Canada
[2] Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
[3] Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institute, Sweden
[4] University of Pittsburgh, Pittsburgh, PA, USA
[5] Magee-Womens Research Institute, Pittsburgh, PA, USA
[6] Department of Pharmaceutics, University of Washington, Seattle, WA, USA
[7] Washington National Primate Research Center, Seattle, WA, USA

Corresponding author: Klatt, Nichole R (klattnr@uw.edu)

Current Opinion in Immunology 2015, **36**:22–30

This review comes from a themed issue on **Host pathogens**

Edited by **Peter A Barry** and **Guido Silvestri**

http://dx.doi.org/10.1016/j.coi.2015.06.004

0952-7915/Published by Elsevier Ltd.

HIV transmission

Extensive research has been dedicated to the development of HIV prevention intervention strategies. A significant challenge in developing these interventions is an incomplete understanding of correlates of sexual transmission including the role of mucosal inflammation. What is exceedingly clear is that increased mucosal inflammation enhances the rate of sexual transmission of HIV at mucosal surfaces [1–3]. Given the recent failure of the HVTN505 [4] and STEP [5] vaccine trials, where increased HIV transmission risk was observed in vaccine recipients, understanding the role of these mechanisms is a growing concern for the HIV prevention field. Recent studies have helped increase our understanding of how sexual activity, inflammation, and host microbiota can influence the mucosal barrier and will be the focus of the transmission portion of this review (Figures 1 and 2a).

Physical and biological barriers for HIV at mucosal surfaces

Routes for HIV transmission include the vagina (and other compartments in the female genital tract; FGT), anus, rectum, and penis/foreskin. These surfaces have both anatomical (epithelial barrier and secreted mucus) and biological barriers (immune cells and antimicrobial factors) to resist viral infection. Per coital frequency of HIV transmission is quite low; approximately 0.1% for unprotected receptive vaginal intercourse and 1.4% for unprotected receptive anal intercourse [6], which demonstrates the effectiveness of these barriers against HIV. The FGT is protected from virus penetration by a multilayered squamous and columnar epithelium in the ectocervix/vaginal vault and endocervix, respectively. On the other hand, the rectal compartment (and other GI sites) is only comprised of a single layer columnar epithelium likely contributing to higher transmission rates. Epithelial integrity at all sites is mediated by protein structures acting to adhere cells to one another (i.e. tight and adherens junctions) or to the extracellular matrix. While the FGT is not considered keratinized, it also contains a layer of flattened differentiated epithelial cells called the stratum corneum which provides further physical and biological barriers to microorganisms [7]. On top of all mucosal surfaces is a layer of secreted mucus, which contains hundreds to thousands of biologically relevant soluble proteins, including immune factors and antimicrobial agents [8], mucins [9] and antiproteases [10,11], which provide immune defense and anti-inflammatory protection against epithelial damage. In addition, mucus itself provides a substantial physical barrier against HIV migration and penetration [12,13].

In order for HIV transmission to occur, infectious virions or infected cells from the donor must cross these barriers to find a susceptible cell in the host. HIV can penetrate as much as 10 μm into the squamous epithelium in the FGT

Figure 1



Similar mechanisms for transmission and pathogenesis in HIV infection.

where target cells reside, which is significantly increased upon tight junction disruption, and migration varies between individuals [14•]. HIV preferentially infects CD4+ T-cells co-expressing CCR5 at mucosal sites [1] and particularly those that are HIV-specific [15] or activated [16•]. Not all CD4+ T-cells are equal, however, and T-helper type 17 (Th17) CD4+ T-cells [17•], as well as activated CD4+ T-cells expressing $\alpha_4\beta_7$ or $\alpha_4\beta_1$ [18], are highly susceptible cells in the FGT compartment. However, the exact mechanism by which HIV infects rectal tissue is uncertain. The rectal lamina propria contains abundant CD4+CCR5+ T-cells that express multiple markers of cell activation, thus key targets for HIV [19]. A network of dendritic cells (DCs) resides within the distal rectum that could facilitate transfer of HIV to target T-cells [20,21,22•]. Another intriguing possibility is that HIV triggers DCs to migrate between rectal epithelial cells, capture virus, and transfer it to activated T-cells in the lamina propria [23]. Therefore immunological factors that affect the number of available target cells, activation status, their accessibility, and/or dissemination, could affect the likelihood of infection.

Mucosal inflammation

Inflammatory responses are largely initiated by epithelial cells, through activation of pattern recognition receptors, to secrete soluble defense factors (antimicrobial peptides, AMPs) and cytokines to stimulate a response from immune cells. HIV can turn this process to its advantage. Indeed, an inflammatory cascade at the mucosal level following virus exposure is required for the establishment of productive viral infection [24]. Although it would seem logical that increase secretion of AMPs that can inhibit HIV infectivity *in vitro* would have the same effect *in vivo*, paradoxically this is not the case. In fact, elevated levels of α-defensins at mucosal surfaces are associated with increased risk of HIV infection [25,26], presumably exacerbating risk by recruiting target cells for infection and/or increasing the susceptibility of cells [27,28]. In addition, increased levels of pro-inflammatory cytokines/chemokines are associated with increased rates of HIV acquisition [29,30••]. Recently, Masson *et al.* demonstrated that in the CAPRISA-004 trial, a 3-fold increased risk of HIV infection was observed in women who had elevated levels of at least five mucosal pro-inflammatory cytokines, including MIP-1α, IL-8, MIP-1β, IL-1β, IL-1α, and TNF-α [30••]. Proteomic analysis by Arnold/Burgener *et al.* demonstrated this pro-inflammatory cytokine profile is linked with increased neutrophil protease levels, barrier disruption, and increased frequency of cervicovaginal CD4+ T-cells [31••]. Thus, a model is proposed that mucosal barrier disruption via neutrophil proteases may drive immune cell migration and frequency, and increase virion access to susceptible cells, and thus the risk of HIV acquisition.

Conversely, *reduced* inflammation and immune activation at mucosal surfaces are associated with HIV protection. Much of this insight has been gained from studying HIV exposed seronegative (HESN) individuals. Decreased immune activation [32], characterized by reduced systemic CD4+ T-cell gene expression [33] coupled with lowered mucosal cytokine/chemokine expression (MIG, IP10, and IL1α) [34] may collectively limit target cell availability and activation and hence reduced risk of infection. Alterations in the mucosal proteome, such as elevated levels of protective serpins, elafin and other antiproteases [35–37], are also associated with protection. Importantly, these factors are essential for *reducing* and *controlling* inflammatory responses [38,39,10,40], particularly due to the direct inhibition of proteases, which are important for immune cell migration, activation, and

Figure 2



Proposed mechanisms of barrier breakdown and inflammation in **(a)** HIV transmission and **(b)** HIV pathogenesis.

tissue barrier breakdown [41]. Indeed, the absence of specific serpins can lead to increased levels of activated Th17+ cells at mucosal surfaces [42], which can be targets of initial infection for HIV [43••]. Furthermore, these antiproteases and their cleavage products have antiviral activity [10,44–46] but are not inherently pro-inflammatory. Therefore it is clear that soluble factors within mucosa are important players in affecting inflammation status of mucosal surfaces and the likelihood of HIV transmission.

Sexual activity and sexually transmitted infections (STIs)

Sexual activity results in increased inflammation and thus may allow an opportunity for HIV transmission [47]. The act of coitus itself can result in microabrasions in the mucosal surface, resulting in wound healing processes and increased vascularity, infiltration and recruitment of immune cells, and increased inflammatory cytokines and proteins [48–50]. In particular, wound healing is associated with neutrophil recruitment, which may increase susceptibility to HIV infection via protease production (described above) [51,52]. Semen itself is highly basic and increases vaginal pH, which may in turn alter the protective mucus layer in the FGT [47,53]. Semen exposure increases pro-inflammatory cytokines in the FGT (such as IL-6, IL-8 and IL-1β) compared to protected coitus or abstinence [54], and is associated with increased CD4+ T-cells and macrophages shortly after coitus [54,55]. Interestingly, progressive sexual exposure, as observed in sex workers from Kenya, results in decreased mucosal immune activation over time [56], suggesting that frequent sexual activity may induce tolerance and precede a reduced immune activation phenotype. Endogenous sex hormones during luteal phase of menses and injectable contraceptives have also been associated with increased HIV infection risk [4,57–63], where progesterone or progestin-based contraceptives may affect HIV target cell levels or host innate immune factors. Recent studies also implicate epithelial tissue remodeling, immune cell movement, and protease levels as potential underlying drivers for this observation [64].

Concurrent STIs also have a strong epidemiological link with increased risk of HIV acquisition. Two of the best-described STIs that increase HIV risk are Herpes simplex virus 2 (HSV-2) and human papilloma virus (HPV); each has been associated with a 2–3 fold increased rate of HIV acquisition in large meta-analyses [65,66]. While the mechanism by which this occurs remains unclear, one hypothesis is that innate host pro/anti-inflammatory mediators modulate HIV susceptibility [67]. Indeed, a higher pro-inflammatory profile characterized by increased numbers of HIV-1 target cells (both CCR5+CD4+ T-cells and DC-SIGN+ DCs) upon HSV-2 infection can persist in mucosal tissues [68,69]. HSV-2 also associates with the amplification of target cells expressing homing markers (α4β7) [70] in the absence of viral shedding and increased activated CD4+CCR5+ T cells (and subsequently higher HIV infectivity) in FGT mucosal explant tissue [71]. Less is known about HPV, although Th1 responses have been linked with HPV clearance [72]. In the rectal compartment, co-infections can be a cause of proctitis in men who have sex with men (MSM) [73,74], and associated with epithelial disruption, inflammation and mucosal ulceration; thus not surprisingly increased risk of HIV acquisition [65,75•]. HPV infection is also prevalent in MSM and associated with an increased risk of HIV acquisition although the mechanism underlying this process is unclear [76]. Thus, STI's may increase HIV target cells and homing to mucosa, and potentially epithelial disruption, but further work is needed to understand these mechanisms given high the prevalence of these STIs and increased risk for HIV.

Microbiota

Changes in vaginal microbial communities are consistently associated with increased HIV risk. This is exemplified by a striking increase in HIV susceptibility with bacterial vaginosis (BV) by as much as 60% [77–79]. BV occurs when protective microbiota in the vagina, dominated by lactic acid-producing *Lactobacillus* species which are associated with protection from HIV transmission [80], are replaced by diverse strains of bacteria such as *Gardnerella*, *Atopobium*, *Prevotella*, *Fusobacterium* spp., and other BV-associated bacteria (BVAB) [79,81]. BV is associated with increased pro-inflammatory cytokine levels, particularly IL-1β [82,83]. Some BVAB are associated with cervicitis in humans [84] which may induce recruitment of T-cells, and treatment of BV with metronidazole led to decreases in mucosal CCR5+CD4+ T-cells [85]. Studies of the mucosal proteome during BV [86] demonstrated lower levels of factors important for an effective physical barrier (small proline-rich proteins and involucrin) [7,87,88]. A recent study by Anahtar *et al.* demonstrated that high ecological diversity of FGT microflora drives enhanced stimulation of TLR4 and NFkB, leading to increased pro-inflammatory cytokines and a subsequent increase in activated CCR5+CD4+ T-cells [89••]. Thus, it is possible that microflora diversity may be an underlying component and/or driver of host inflammation responses and HIV acquisition.

Less is known about the role of the rectal microbiome and HIV transmission. It has been hypothesized that the diversity of sexual repertoire and the number of sexual partners found in many MSM may create a novel ecosystem that facilitates the generation and transmission of antibiotic resistant *Neisseria gonorrhea* infection. It remains to be seen whether this ecosystem might also facilitate HIV transmission. Although dysbiosis of gut microbiota increases with progressive HIV infection (discussed below) [90,91•], it is not clear whether the gut microbiota of HIV-negative MSM differs from that seen in HIV-negative heterosexual men. Given that the interactions of the

microbiota with the host may lead to significant changes in the mucosal barrier altered HIV susceptibility, understanding these mechanisms may uncover important microbial targets for biomedical intervention.

Taken together, further studies of the mechanism of how these inflammatory/anti-inflammatory mediators lead to HIV infection risk at mucosal surfaces may shed light on susceptibility mechanisms and targeted strategies for prevention technology development.

Pathogenesis

Once HIV infection occurs, the mucosal landscape is dramatically and rapidly altered. While the underlying mechanisms of this are unclear, what is evident is that destruction to the mucosal tissues is substantial and not completely reversible with ART. Here we will review recent evidence that demonstrate how multiple factors impact barrier integrity during HIV infection and contribute to host pathogenesis to HIV (Figure 2b).

Barrier

While early studies reported damage to the GI tract and alterations in mucosal immunity after HIV infection, the first indication that barrier function was involved in pathogenesis came from influential work from Brenchley *et al.* demonstrating that microbial products translocate during HIV infection [92,93]. The mechanism for microbial translocation was subsequently demonstrated to be focal breaches that occur in the GI tract during HIV infection, allowing microbial products to translocate from the lumen [94,95], thus further driving inflammation. More recently, the consequences of barrier damage in HIV infection in mortality has been further highlighted. Namely, Hunt *et al.* demonstrated that soluble factors in periphery associated with barrier damage, including the tight junction protein zonulin, and the epithelial death biomarker intestinal fatty acid binding protein (I-FABP) predict mortality in HIV infected individuals [96••]. Furthermore, studies in the SIV model have demonstrated that *preexisting* barrier damage before SIV infection predicts disease progression to AIDS after infection [97•], demonstrating the importance of barrier health even before infection occurs.

Homeostatic immunity

Studies of early infection during HIV have been limited due to difficulty in both early diagnoses of HIV as well as obtaining samples during these early time points. A major contribution to our understanding of acute HIV infection has been by Schuetz *et al.*, where mucosal samples were collected in acute HIV infection, and patients were initiated on ART extremely early [98••]. These studies demonstrated that several key immunological components are altered early in HIV infection including rapid loss of Th17 cells in Feibig III, which is not reversible unless ART is initiated early in Fiebig I/II [98••]. Additionally, Th17 cells are rapidly lost in the FGT after HIV infection, demonstrating that multiple mucosal sites are targets [43••]. Th17 cells are of particular interest in the context of mucosal immunology given that these cells are critical in mucosal homeostasis, and loss of Th17 cells in chronic HIV infection has been associated with damage to the tight epithelial barrier and ensuing microbial translocation [99–101]. While it is promising that early ART treatment can prevent Th17 loss, it should be noted that the reality of being able to treat as early as Fiebig I/II, or essentially two weeks after infection, would be nearly impossible. Thus, further understanding of the early kinetics of Th17 loss, why they are an early target, and their relationship to overall CD4+ T-cell depletion and pathogenesis, will be important for treatment strategies.

Immune activation

HIV-associated inflammation is one of the most unequivocally clear consequences of HIV infection and is highly associated with disease progression, morbidities and mortality, independent of antiretroviral therapy (ART) [102,103]. HIV itself can directly induce inflammation via stimulation of immune cells and induction of both innate and adaptive arms of the immune system [103]. However, it is likely that the majority of the inflammation in HIV infection is via indirect or 'bystander' mechanisms, due to factors such as microbial translocation, CMV reactivation, and other mechanisms, which can both cause and be an effect of CD4+ T-cell depletion [102]. Recently, a novel mechanism for inflammation and CD4+ T-cell depletion was described, whereby Doitsch *et al.* demonstrated that caspase-1 driven pyroptosis results in the spilling of cytosolic contents, containing highly inflammatory cytokines, namely IL-1β [104••]. The major consequence of this chronic inflammation is increased morbidities and mortality, highlighting the need to more precisely delineate factors underlying inflammation in HIV-infected individuals.

Microbiome

Several recent studies have highlighted that dysbiosis of the microbiome during HIV infection is associated with mucosal dysfunction. Vujkovic-Cvijin *et al.* recently demonstrated that during HIV infection, adherent bacteria such as Proteobacteria are enriched in the intestinal mucosa, together with depletion of Bacteroidia bacteria, which is associated with disease progression [91•]. The proposed mechanism by which this dysbiosis drives disease is by the ability for these bacteria to stimulate kynurenine pathways of tryptophan catabolism [91•], which is known to depress Th17 cells and associated with disease progression in HIV [96••,105,106,107••]. Dysbiosis can also directly alter immune cells in the GI tract; Dillon *et al.* demonstrated that increased Prevotella and Proteobacteria, together with decreased Firmicutes and Bacteroidetes in HIV infection is associated with increased T-cell and myeloid DC (mDC)

activation [108••]. In addition, mDCs can be directly stimulated by HIV-altered mucosal bacteria (HAMBs), which are associated with T-cell activation [109•]. Finally, Klase *et al.* demonstrated that in SIV-infected macaques, Proteobacteria were not only increased, but more metabolically active, and were identified as the major bacteria group that translocate during lentiviral infection [110••]. Taken together, it is clear that dysbiosis of the microbiome occurs during HIV infection, and is associated with microbial translocation and inflammation. However, given that this dysbiosis is associated with increased adherent Proteobacteria species, it can be hypothesized that these HAMBs could directly induce damage to the mucosal barrier. However, the precise mechanism of this damage is unknown and should be further studied.

Barrier function and soluble factors

While transmission studies clearly demonstrate that soluble factors including proteases and extracellular matrix proteins are associated with inflammation and increased HIV acquisition [31••], factors such as these have been largely understudied in terms of pathogenesis and will be essential to investigate. Transcriptional analysis of gut tissues in the SIV model has demonstrated that SIV infection is associated with decreased genes encoding for cell adhesion [111•] as well as a decrease in genes regulating focal adhesions, gap junctions and Wnt signaling in intestinal epithelium [112]. In addition, neutrophils have been shown to accumulate at high levels in the GI tissue of HIV infected individuals [107••]. Neutrophils secrete several inflammatory soluble factors that could contribute to inflammation and barrier disruption [31••], and could be a major contributor to GI dysfunction in the context of HIV. These data indicate that alterations in protein expression would therefore probably be altered and may contribute to a damaged mucosal barrier.

Conclusions

While the phenomena here are well described in both contributing to HIV transmission and pathogenesis, the specific mechanisms underlying these dysfunctions of the barrier are still unclear. To date, while there are many studies which have provided crucial information in regards to characterizing mucosal defects and HIV transmission or pathogenesis, we still lack specific mechanisms and thus targets to decrease HIV-associated disease. Overall, many issues are important for host barrier interactions in the context of HIV but remain unresolved. What is clear is that barrier function is a key parameter in both acquisition and pathogenesis of HIV infection, and determining specifically what induces inflammation, barrier breakdown, and altered microbiome will be critical in developing more effective prevention and treatment strategies for HIV infection.

References and recommended reading

Papers of particular interest, published within the period of review,

have been highlighted as:

- • of special interest
- •• of outstanding interest

1. Haase AT: **Early events in sexual transmission of HIV and SIV and opportunities for interventions**. *Annu Rev Med* 2011, **62**:127-139.
2. Kaul R, Ball TB, Hirbod T: **Defining the genital immune correlates of protection against HIV acquisition: co-infections and other potential confounders**. *Sex Transm Infect* 2011, **87**:125-130.
3. Naranbhai V *et al.*: **Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel**. *J Infect Dis* 2012, **206**:993-1001.
4. Hammer SM *et al.*: **Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine**. *N Engl J Med* 2013, **369**:2083-2092.
5. Walker BD, Burton DR: **Toward an AIDS vaccine**. *Science* 2008, **320**:760-764.
6. Baggaley RF, White RG, Boily MC: **HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention**. *Int J Epidemiol* 2010, **39**:1048-1063.
7. Anderson DJ, Marathe J, Pudney J: **The structure of the human vaginal stratum corneum and its role in immune defense**. *Am J Reprod Immunol* 2014, **71**:618-623.
8. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM: **Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid**. *J Immunol* 2005, **175**:7560-7567.
9. Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA: **Mucins in the mucosal barrier to infection**. *Mucosal Immunol* 2008, **1**:183-197.
10. Aboud L, Tjernlund A, Ball TB, Burgener A: **The role of serpin and cystatin antiproteases in mucosal innate immunity and their defense against HIV**. *Am J Reprod Immunol* 2013, **71**:12-23.
11. Silverman GA *et al.*: **Serpins flex their muscle: I. Putting the clamps on proteolysis in diverse biological systems**. *J Biol Chem* 2010, **285**:24299-24305.
12. Miller CJ *et al.*: **Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus**. *J Virol* 2005, **79**:9217-9227.
13. Shukair SA *et al.*: **Human cervicovaginal mucus contains an activity that hinders HIV-1 movement**. *Mucosal Immunol* 2013, **6**:427-434.
14. • Carias AM *et al.*: **Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract**. *J Virol* 2013, **87**:11388-11400.

Authors use human tissue explants to demonstrate that HIV-1 enters squamous epithelium via diffusive percolation.

15. Douek DC *et al.*: **HIV preferentially infects HIV-specific CD4+ T cells**. *Nature* 2002, **417**:95-98.
16. • Carnathan DG *et al.*: **Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques**. *Proc Natl Acad Sci U S A* 2015, **112**:518-523.

Authors demonstrated that in vaccinated macaques, the levels of rectal target cells (CD4+CCR5+HLA-DR+ T cells) correlated with increased acquisition of SIV, while SIV-specific CD8 responses did not associate with protection.

17. • Rodriguez-Garcia M, Barr FD, Crist SG, Fahey JV, Wira CR: **Phenotype and susceptibility to HIV infection of CD4+ Th17 cells in the human female reproductive tract**. *Mucosal Immunol* 2014, **7**:1375-1385.

This study demonstrates that Th17 cells in the FGT (particularly those that express CCR5 and CD90) are most susceptible to HIV infection.

18. Joag VR *et al.*: **Identification of preferential CD4 T-cell targets for HIV infection in the cervix**. *Mucosal Immunol* 2015. Advanced online publication.

19. Poles MA, Elliott J, Taing P, Anton PA, Chen IS: **A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection**. *J Virol* 2001, **75**:8390-8399.

20. Allers K *et al.*: **Macrophages accumulate in the gut mucosa of untreated HIV-infected patients**. *J Infect Dis* 2014, **209**:739-748.

21. McElrath MJ *et al.*: **Comprehensive assessment of HIV target cells in the distal human gut suggests increasing HIV susceptibility toward the anus**. *J Acquir Immune Defic Syndr* 2013, **63**:263-271.

22. • Preza GC *et al.*: **Antigen-presenting cell candidates for HIV-1 transmission in human distal colonic mucosa defined by CD207 dendritic cells and CD209 macrophages**. *AIDS Res Hum Retroviruses* 2014, **30**:241-249.

This study describes antigen presenting cells in the lower GI tract (namely Langherhan cells and macrophage-like DCs that express DC-SIGN) which may facilitate HIV infection in MSM.

23. Cavarelli M, Foglieni C, Rescigno M, Scarlatti G: **R5 HIV-1 envelope attracts dendritic cells to cross the human intestinal epithelium and sample luminal virions via engagement of the CCR5**. *EMBO Mol Med* 2013, **5**:776-794.

24. Li Q *et al.*: **Glycerol monolaurate prevents mucosal SIV transmission**. *Nature* 2009, **458**:1034-1038.

25. Hirbod T *et al.*: **HIV acquisition is associated with increased antimicrobial peptides and reduced HIV neutralizing IgA in the foreskin prepuce of uncircumcised men**. *PLoS Pathog* 2014, **10**:e1004416.

26. Levinson P *et al.*: **Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition**. *AIDS* 2009, **23**:309-317.

27. Ogawa Y *et al.*: **Antimicrobial peptide LL-37 produced by HSV-2-infected keratinocytes enhances HIV infection of Langerhans cells**. *Cell Host Microbe* 2013, **13**:77-86.

28. Yang D, Chertov O, Oppenheim JJ: **Participation of mammalian defensins and cathelicidins in anti-microbial immunity: receptors and activities of human defensins and cathelicidin (LL-37)**. *J Leukoc Biol* 2001, **69**:691-697.

29. Mlisana K *et al.*: **Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa**. *J Infect Dis* 2012, **206**:6-14.

30. •• Masson L *et al.*: **Genital inflammation and the risk of HIV acquisition in women**. *Clin Infect Dis* 2015.

This study linked genital pro-inflammatory cytokine levels, in the absence of STI's, with increased risk (3.2 fold) of HIV infection in women from South Africa (especially target cell-recruiting chemokines MIP-1α, MIP-1β and IP-10) which were persistently raised before seroconversion. These could be important drivers of HIV acquisition.

31. •• Arnold K *et al.*: **Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV susceptible target cells**. *Mucosal Immunol* 2015. in press.

This proteomic and systems biology analysis of mucosal samples from women revealed strong linkages between elevated mucosal cytokines, barrier function, proteases, immune cell movement with HIV-target cell numbers within the female genital tract, helping to understand down-stream consequences of mucosal inflammation and mechanisms of increased susceptibility to HIV infection.

32. Card CM, Ball TB, Fowke KR: **Immune quiescence: a model of protection against HIV infection**. *Retrovirology* 2013, **10**:141.

33. McLaren PJ *et al.*: **HIV-exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV-dependent host factors**. *J Infect Dis* 2010, **202(Suppl 3)**:S339-S344.

34. Lajoie J *et al.*: **A distinct cytokine and chemokine profile at the genital mucosa is associated with HIV-1 protection among HIV-exposed seronegative commercial sex workers**. *Mucosal Immunol* 2012, **5**:277-287.

35. Burgener A *et al.*: **Comprehensive proteomic study identifies serpin and cystatin antiproteases as novel correlates of HIV-1 resistance in the cervicovaginal mucosa of female sex workers**. *J Proteome Res* 2011, **10**:5139-5149.

36. Burgener A *et al.*: **Identification of differentially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers**. *J Proteome Res* 2008, **7**:4446-4454.

37. Iqbal SM *et al.*: **Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition**. *AIDS* 2009, **23**:1669-1677.

38. Pott GB, Chan ED, Dinarello CA, Shapiro L: **Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood**. *J Leukoc Biol* 2009, **85**:886-895.

39. Ashton-Rickardt PG: **Serine protease inhibitors and cytotoxic T lymphocytes**. *Immunol Rev* 2010, **235**:147-158.

40. Benarafa C, Priebe GP, Remold-O'Donnell E: **The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in *Pseudomonas aeruginosa* infection**. *J Exp Med* 2007, **204**:1901-1909.

41. Kolaczkowska E, Kubes P: **Neutrophil recruitment and function in health and inflammation**. *Nat Rev Immunol* 2013, **13**:159-175.

42. Zhao P, Hou L, Farley K, Sundrud MS, Remold-O'Donnell E: **SerpinB1 regulates homeostatic expansion of IL-17+ gammadelta and CD4+ Th17 cells**. *J Leukoc Biol* 2014, **95**:521-530.

43. •• McKinnon LR *et al.*: **Early HIV-1 infection is associated with reduced frequencies of cervical Th17 cells**. *J Acquir Immune Defic Syndr* 2015, **68**:6-12.

This study demonstrates that Th17 cells are preferentially lost from the FGT (>10-fold loss) in early HIV compared to Th1 cells (2-fold loss), indicating rapid decline of CD4:CD8 ratio in both blood and FGT may be due to Th17 loss.

44. Munch J *et al.*: **Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide**. *Cell* 2007, **129**:263-275.

45. Ghosh M *et al.*: **Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract**. *Immunology* 2009, **129**:207-219.

46. Whitney JB, Asmal M, Geiben-Lynn R: **Serpin induced antiviral activity of prostaglandin synthetase-2 against HIV-1 replication**. *PLoS One* 2011, **6**:e18589.

47. Southern PJ: **Missing out on the biology of heterosexual HIV-1 transmission**. *Trends Microbiol* 2013, **21**:245-252.

48. Allavena P, Sica A, Solinas G, Porta C, Mantovani A: **The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages**. *Crit Rev Oncol Hematol* 2008, **66**:1-9.

49. Maslinska D, Gajewski M: **Some aspects of the inflammatory process. Folia neuropathologica/Association of Polish Neuropathologists and Medical Research Centre**. *Pol Acad Sci* 1998, **36**:199-204.

50. Punchard NA, Whelan CJ, Adcock I: **The Journal of Inflammation**. *J Inflamm* 2004, **1**:1.

51. Wilgus TA, Roy S, McDaniel JC: **Neutrophils and wound repair: positive actions and negative reactions**. *Adv Wound Care* 2013, **2**:379-388.

52. Mackelprang RD *et al.*: **Genital proteome correlates of highly HIV-1 exposed uninfected African women**. *AIDS Res Hum Retroviruses* 2014, **30(Suppl 1)**:A82.

53. Lai SK *et al.*: **Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus**. *J Virol* 2009, **83**:11196-11200.

54. Sharkey DJ, Tremellen KP, Jasper MJ, Gemzell-Danielsson K, Robertson SA: **Seminal fluid induces leukocyte recruitment**

and cytokine and chemokine mRNA expression in the human cervix after coitus. *J Immunol* 2012, **188**:2445-2454.

55. Prakash M, Patterson S, Gotch F, Kapembwa MS: **Recruitment of CD4 T lymphocytes and macrophages into the cervical epithelium of women after coitus**. *Am J Obst Gynecol* 2003, **188**:376-381.

56. Lajoie J *et al.*: **Association of sex work with reduced activation of the mucosal immune system**. *J Infect Dis* 2014, **210**:319-329.

57. Heffron R *et al.*: **Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study**. *Lancet Infect Dis* 2012, **12**:19-26.

58. Morrison CS *et al.*: **Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis**. *PLoS Med* 2015, **12**:e1001778.

59. Wira CR, Fahey JV: **A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle**. *AIDS* 2008, **22**:1909-1917.

60. Kersh EN *et al.*: **SHIV susceptibility changes during the menstrual cycle of pigtail macaques**. *J Med Primatol* 2014, **43**:310-316.

61. Vishwanathan SA *et al.*: **High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques**. *J Acquir Immune Defic Syndr* 2011, **57**:261-264.

62. Sodora DL, Gettie A, Miller CJ, Marx PA: **Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks**. *AIDS Res Hum Retroviruses* 1998, **14(Suppl 1)**: S119-S123.

63. Saba E *et al.*: **Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of the menstrual cycle**. *Mucosal Immunol* 2013, **6**:1081-1090.

64. Birse K *et al.*: **Molecular signatures of immune activation and epithelial barrier remodeling are enhanced during the luteal phase of the menstrual cycle: implications for HIV susceptibility**. *J Virol* 2014. Advanced online publication.

65. Freeman EE *et al.*: **Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies**. *AIDS* 2006, **20**:73-83.

66. Houlihan CF *et al.*: **Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis**. *AIDS* 2012, **26**:2211-2222.

67. Kaul R *et al.*: **The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission**. *J Reprod Immunol* 2008, **77**:32-40.

68. Rebbapragada A *et al.*: **Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract**. *AIDS* 2007, **21**:589-598.

69. Zhu J *et al.*: **Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition**. *Nat Med* 2009, **15**:886-892.

70. Martinelli E *et al.*: **HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target**. *PLoS Pathog* 2011, **7**:e1002109.

71. Rollenhagen C, Lathrop MJ, Macura SL, Doncel GF, Asin SN: **Herpes simplex virus type-2 stimulates HIV-1 replication in cervical tissues: implications for HIV-1 transmission and efficacy of anti-HIV-1 microbicides**. *Mucosal Immunol* 2014, **7**:1165-1174.

72. Scott M, Stites DP, Moscicki AB: **Th1 cytokine patterns in cervical human papillomavirus infection**. *Clin Diagn Lab Immunol* 1999, **6**:751-755.

73. Bissessor M *et al.*: **The etiology of infectious proctitis in men who have sex with men differs according to HIV status**. *Sex Transm Dis* 2013, **40**:768-770.

74. Hoentjen F, Rubin DT: **Infectious proctitis: when to suspect it is not inflammatory bowel disease**. *Dig Dis Sci* 2012, **57**:269-273.

75. Marcus U *et al.*: **Risk factors for HIV and STI diagnosis in a community-based HIV/STI testing and counselling site for men having sex with men (MSM) in a large German city in 2011-2012**. *BMC Infect Dis* 2015, **15**:14.

• This study found a correlation with increased HIV susceptibility in MSM and the presence of rectal STIs or bacterial infections, indicating the importance of monitoring for rectal co-infections in HIV prevention in the MSM population.

76. Welling CA *et al.*: **Association of HIV infection with anal and penile low-risk human papillomavirus infections among men who have sex with men in Amsterdam: the HIV & HPV in MSM study**. *Sex Transm Dis* 2015, **42**:297-304.

77. Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS: **Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies**. *AIDS* 2008, **22**:1493-1501.

78. Mirmonsef P, Krass L, Landay A, Spear GT: **The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract**. *Curr HIV Res* 2012, **10**:202-210.

79. Schellenberg JJ *et al.*: **Bacterial vaginosis, HIV serostatus and T-cell subset distribution in a cohort of East African commercial sex workers: retrospective analysis**. *AIDS* 2012, **26**:387-393.

80. Borgdorff H *et al.*: **Lactobacillus-dominated cervicovaginal microbiota associated with reduced HIV/STI prevalence and genital HIV viral load in African women**. *ISME J* 2014, **8**:1781-1793.

81. Srinivasan S *et al.*: **Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria**. *PLoS ONE* 2012, **7**:e37818.

82. Marconi C *et al.*: **Cervicovaginal levels of proinflammatory cytokines are increased during chlamydial infection in bacterial vaginosis but not in lactobacilli-dominated flora**. *J Low Genit Tract Dis* 2014, **18**:261-265.

83. Masson L *et al.*: **Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study**. *Sex Transm Infect* 2014, **90**:580-587.

84. Sycuro LK, Gorgos LM, Fiedler TL, Srinivasan S, Marrazzo JM, Fredricks DN: **Association of *Mageebacillus indolicus* (BVAB-3) with cervicitis suggests teh virulence potential of this novel vaginal bacterium**. *Am Soc Microbiol* 2012. Abstract.

85. Rebbapragada A *et al.*: **Bacterial vaginosis in HIV-infected women induces reversible alterations in the cervical immune environment**. *J Acquir Immune Defic Syndr* 2008, **49**:520-522.

86. Arnold K *et al.*: **Mucosal integrity factors are perturbed during bacterial vaginosis: a proteomic analysis**. *AIDS Res Hum Retroviruses* 2014, **30**:A30.

87. Kalinin AE, Kajava AV, Steinert PM: **Epithelial barrier function: assembly and structural features of the cornified cell envelope**. *Bioessays* 2002, **24**:789-800.

88. Dinh MH, McRaven MD, Kelley Z, Penugonda S, Hope TJ: **Keratinization of the adult male foreskin and implications for male circumcision**. *AIDS* 2010, **24**:899-906.

89. Anahtar MN *et al.*: **Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract**. *Immunity* 2015, **42**:965-976.

•• This microbiome study described the relationship between microbial diversity in the female genital tract to increased TLR signaling by epithelial cells, mucosal cytokines, and increased recruitment of HIV target cells.

90. Yu G, Fadrosh D, Ma B, Ravel J, Goedert JJ: **Anal microbiota profiles in HIV-positive and HIV-negative MSM**. *AIDS* 2014, **28**:753-760.

91. Vujkovic-Cvijin I *et al.*: **Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism**. *Sci Transl Med* 2013, **5**:193ra191.

• The authors find that HIV infection results in dysbiosis of the microbiome, consisting of increased adherent bacteria, which is associated with increased tryptophan catabolism, which may underlie immunological dysfunction in the GI tract.

92. Brenchley JM, Price DA, Douek DC: **HIV disease: fallout from a mucosal catastrophe?** *Nat Immunol* 2006, **7**:235-239.

93. Brenchley JM *et al.*: **Microbial translocation is a cause of systemic immune activation in chronic HIV infection**. *Nat Med* 2006, **12**:1365-1371.

94. Estes JD *et al.*: **Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections**. *PLoS Pathog* 2010, **6**:e1001052.

95. Nazli A *et al.*: **Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation**. *PLoS Pathog* 2010, **6**:e1000852.

96. •• Hunt PW *et al.*: **Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection**. *J Infect Dis* 2014.
This study demonstrates that increased mortality in HIV-infected individuals is associated with systemic markers of GI barrier integrity, indicating the importance of barrier damage in driving pathogenesis in HIV infection.

97. • Canary LA *et al.*: **Rate of AIDS progression is associated with gastrointestinal dysfunction in simian immunodeficiency virus-infected pigtail macaques**. *J Immunol* 2013, **190**:2959-2965.
This study demonstrates that decreased GI barrier integrity in healthy macaques results in increased progression to AIDS upon SIV infection, indicating that pre-existing mucosal health is a factor associated with HIV pathogenesis.

98. •• Schuetz A *et al.*: **Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation**. *PLoS Pathog* 2014, **10**:e1004543.
The authors find that Th17 cells in the GI tract are lost early in HIV infection and associated with mucosal and systemic inflammation; Th17 could be preserved only by early (Fiebig I/II) initiation of ART.

99. Klatt NR *et al.*: **Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection**. *Mucosal Immunol* 2012, **5**:646-657.

100. Klatt NR, Brenchley JM: **Th17 cell dynamics in HIV infection**. *Curr Opin HIV AIDS* 2010, **5**:135-140.

101. Brenchley JM *et al.*: **Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections**. *Blood* 2008, **112**:2826-2835.

102. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW: **Residual immune dysregulation syndrome in treated HIV infection**. *Adv Immunol* 2013, **119**:51-83.

103. Klatt NR, Chomont N, Douek DC, Deeks SG: **Immune activation and HIV persistence: implications for curative approaches to HIV infection**. *Immunol Rev* 2013, **254**:326-342.

104. •• Doitsh G *et al.*: **Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection**. *Nature* 2014, **505**:509-514.
This study demonstrates that pyroptosis of CD4+ T cells may underlie CD4 depletion and inflammation in HIV infection, associated with increased IL-1β.

105. Favre D *et al.*: **Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease**. *Sci Transl Med* 2010, **2**:32ra36.

106. Serrano-Villar S *et al.*: **HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality**. *PLoS Pathog* 2014, **10**:e1004078.

107. •• Somsouk M *et al.*: **Gut epithelial barrier and systemic inflammation during chronic HIV infection**. *AIDS* 2015, **29**:43-51.
The authors find that increased neutrophil accumulation and epithelial apoptosis in the GI tract occurs during HIV infection despite ART, and may underlie chronic mucosal dysfunction.

108. •• Dillon SM *et al.*: **An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia**. *Mucosal Immunol* 2014, **7**:983-994.
This study describes specific HAMBs, and demonstrates that dysbiosis in HIV infection can drive inflammation.

109. • Dillon SM *et al.*: **Gut dendritic cell activation links an altered colonic microbiome to mucosal and systemic T cell activation in untreated HIV-1 infection**. *Mucosal Immunol* 2015. (in press, advanced online publication).
The authors describe that HAMBs can drive dendritic cell activation, which drives T cell activation in the gut and periphery.

110. •• Klase Z *et al.*: **Dysbiotic bacteria translocate in progressive SIV infection**. *Mucosal Immunol* 2015. Advanced online publication.
This study demonstrates that Proteobacteria preferentially translocate in SIV-infected macaques, indicating that dysbiotic bacteria in HIV infection also are those that may underlie microbial translocation.

111. • Barrenas F *et al.*: **Deep transcriptional sequencing of mucosal challenge compartment from rhesus macaques acutely infected with simian immunodeficiency virus implicates loss of cell adhesion preceding immune activation**. *J Virol* 2014, **88**:7962-7972.
These data demonstrate that mucosal integrity is rapidly decreased after SIV infection of macaques, and occurs before peak viremia or inflammation, potentially enabling rapid inflammation and further tissue damage.

112. Mohan M *et al.*: **Focused examination of the intestinal epithelium reveals transcriptional signatures consistent with disturbances in enterocyte maturation and differentiation during the course of SIV infection**. *PLoS One* 2013, **8**:e60122.